20260805_160021.jpg
Check and provide each and everything
analyse_media
Reading File
Here is the complete, organized breakdown of everything on this prescription sheet:
Patient Details
| Field | Info |
|---|---|
| Name | B. Vijay Laxmi, Bhupal |
| Gender | Female |
| Age | 50 years old |
Diagnoses (D/s)
- AFI - Acute Febrile Illness
- LKT I - Likely refers to Left Kidney / or a related diagnosis (context-dependent)
- OAD - Obstructive Airway Disease
- Pulmonary Fibrosis (Bilateral lung fibrosis - noted as "B/L lung fibrosis")
Vitals / On Examination (O/E)
| Parameter | Value |
|---|---|
| Patient State | Conscious, oriented (C/C) |
| Temperature | 99.6°F |
| BP (Blood Pressure) | 140/100 mmHg |
| PR (Pulse Rate) | 104/min |
| SpO2 | 97% (written as CPO2 or SpO2) |
Co-morbidities / Background
- K/C/O (Known Case Of): Renovascular HTN (Hypertension)
- C/O: General weakness + Anemia (written as "Anaemia" / "General weakness")
Drug Prescription
Syrups
| # | Drug | Dose | Route | Frequency |
|---|---|---|---|---|
| 1 | Syp. Pulmolear (Ambroxol / mucolytic combo) | 5 ml | P/O | Twice daily |
| 2 | Syp. Zincovit | 5 ml | P/O | Once daily |
| 3 | Syp. Muconget | 10 ml | P/O | Twice daily (STOP noted) |
Tablets
| # | Drug | Dose | Route | Frequency | Notes |
|---|---|---|---|---|---|
| 1 | Tab. Pantop (Pantoprazole) | 40 mg | P/O | Once daily | |
| 2 | Tab. CINOD (Cinnarizine + Domperidone) | 10 mg | P/O | Twice daily | STOP noted |
| 3 | Tab. Mirago (Mirtazapine) | 25 mg | P/O | Once daily | |
| 4 | Tab. Librax (Chlordiazepoxide + Clidinium) | 1 tab (15 mg) | P/O | Once daily | |
| 5 | Tab. Mini Pren (Minipress / Prazosin) | 5 ml / 8/10 mg | P/O | Once daily | STOP noted (crossed out) |
| 6 | Tab. Nebistar (Nebivolol) | 1 mg | P/O | Once daily |
Nebulization
| # | Drug | Dose | Route | Frequency |
|---|---|---|---|---|
| 1 | Neb. Nebzmart (likely Levosalbutamol + Ipratropium) | 1 amp | P/O (via nebulizer) | Thrice daily |
Special Instructions
- 7. Quino hike - Likely Quinolone antibiotic (e.g., Levofloxacin/Ofloxacin) - OD x 10 days (Once daily for 10 days)
- (STOP) noted against Tab. CINOD, Syp. Muconget, and Tab. Mini Pren - these drugs have been discontinued/crossed out
Summary of Clinical Picture
This is a 50-year-old female with:
- Acute febrile illness being treated with a quinolone antibiotic for 10 days
- Bilateral pulmonary fibrosis + OAD managed with nebulization (Nebzmart), mucolytic syrup (Pulmolear)
- Renovascular hypertension managed with Nebivolol (Beta-blocker); Minipress/Prazosin was previously prescribed but STOPPED
- Anemia being addressed with Zincovit (zinc + vitamins)
- GI protection via Pantoprazole
- Mirtazapine (Mirago 25 mg) suggests appetite stimulation or mild depression/anxiety
- Librax for GI spasm / anxiety
- Some drugs (CINOD, Muconget, Mini Pren) have been marked STOP, indicating they were previously on the regimen and now discontinued
Note: Some handwriting was partially illegible; interpretations above are based on context and common drug names used in Indian clinical practice. Always verify with the prescribing physician before dispensing.
17859265676265548326154288954124.jpg
17859265879361112566294630031378.jpg
Read the case and check the moa adrs side effects drug drug interaction prescription reconciliation
analyse_media
analyse_media
Now I have the full case. Let me search the medical library for the key drugs in parallel.
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Searching the Web
drug interactions mirtazapine nebivolol levofloxacin QT prolongation chlordiazepoxide
Here is the complete clinical pharmacology review for this prescription:
CLINICAL PHARMACOLOGY REVIEW
Patient: B. Vijay Laxmi | Female | 50 years
Diagnoses: AFI, LRTI, OAD, Bilateral Pulmonary Fibrosis
K/C/O: Hypertension (Renovascular), Anemia
Vitals: Temp 99.6°F | BP 140/100 mmHg | PR 104/min | SpO2 97%
COMPLETE DRUG LIST (Active Prescription)
| # | Drug (Brand) | Generic | Dose | Route | Frequency |
|---|---|---|---|---|---|
| 1 | Syp. Pulmoclear | Ambroxol + Guaifenesin | 5 ml | PO | BD |
| 2 | Syp. Zincovit | Zinc + Multivitamins | 5 ml | PO | OD |
| 3 | Syp. Muconget | Acetylcysteine/Carbocisteine | 10 ml | PO | BD |
| 4 | Tab. Pantop | Pantoprazole | 40 mg | PO | OD |
| 5 | Tab. CINOD | Cinnarizine + Domperidone | 10 mg | PO | BD |
| 6 | Tab. Mirago | Mirtazapine | 25 mg (likely 7.5/15 mg) | PO | OD |
| 7 | Tab. Librax | Chlordiazepoxide 5 mg + Clidinium 2.5 mg | 1 tab | PO | OD |
| 8 | Tab. Nebistar | Nebivolol | 5 mg | PO | OD |
| 9 | Neb. Nebzmart | Levosalbutamol + Ipratropium | 1 amp | Nebulization | TID |
| 10 | Tab. Quinohike | Levofloxacin 500 mg | 1 tab | PO | OD x 10 days |
| - |
SECTION 1: MECHANISM OF ACTION (MOA)
1. Syp. Pulmoclear (Ambroxol + Guaifenesin)
MOA:
- Ambroxol: Mucokinetic agent. Stimulates surfactant production by type II pneumocytes, reduces sputum viscosity by breaking disulfide bonds in mucus glycoproteins, increases ciliary beat frequency, and promotes mucociliary clearance.
- Guaifenesin: Expectorant. Increases respiratory tract fluid secretion, hydrates mucus, reduces adhesiveness, making it easier to expectorate.
2. Syp. Muconget (Acetylcysteine / N-acetylcysteine)
MOA: Mucolytic. Breaks disulfide (-S-S-) bonds in mucus glycoproteins via its free sulfhydryl (-SH) group, directly reducing the viscosity and elasticity of mucus. Also acts as an antioxidant (glutathione precursor), which may benefit in pulmonary fibrosis.
3. Syp. Zincovit (Zinc + B-vitamins + Vitamin C)
MOA: Zinc is a cofactor for >300 enzymatic reactions, essential for immune function, erythropoiesis, and wound healing. B-vitamins (B12, folic acid, B6) are required for red blood cell maturation - important here for anemia.
4. Tab. Pantoprazole (Pantop 40 mg)
MOA: Irreversible proton pump inhibitor (PPI). Covalently binds and inhibits H+/K+-ATPase (the proton pump) on the luminal surface of gastric parietal cells. This blocks the final step of acid secretion, reducing gastric acid output by up to 98%.
5. Tab. CINOD (Cinnarizine + Domperidone)
MOA:
- Cinnarizine: Calcium channel blocker (vascular) + H1 antihistamine. Blocks Ca2+ entry in smooth muscle, causes cerebral vasodilation, reduces vestibular excitability - used for vertigo/nausea.
- Domperidone: Dopamine D2 receptor antagonist (peripheral). Acts on the chemoreceptor trigger zone (CTZ) and gastric wall - prokinetic and antiemetic. Does NOT cross BBB significantly.
6. Tab. Mirago (Mirtazapine 25 mg)
MOA (NaSSA - Noradrenergic and Specific Serotonergic Antidepressant):
- Blocks presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors → increases release of both norepinephrine (NE) and serotonin (5-HT)
- Simultaneously blocks 5-HT2A, 5-HT2C, and 5-HT3 receptors → channels serotonin selectively through 5-HT1A receptors, reducing nausea and sexual side effects
- Strong H1 histamine blockade → sedation and appetite stimulation (useful here for anorexia/weakness)
- (Source: Stahl's Essential Psychopharmacology)
7. Tab. Librax (Chlordiazepoxide 5 mg + Clidinium 2.5 mg)
MOA:
- Chlordiazepoxide: Benzodiazepine. Positive allosteric modulator at GABA-A receptors → increases frequency of Cl- channel opening → hyperpolarization → anxiolytic, muscle relaxant.
- Clidinium: Anticholinergic (muscarinic antagonist) → reduces GI smooth muscle spasm, decreases gastric acid secretion.
- Combination used for anxiety with GI spasm (irritable bowel-type symptoms).
8. Tab. Nebistar (Nebivolol 5 mg)
MOA: Third-generation beta-1 selective adrenoceptor blocker + stimulates beta-3 receptors → increases NO (nitric oxide) production via endothelial eNOS → vasodilation. Results in reduced heart rate, reduced cardiac output, and vasodilation. Has metabolically neutral profile compared to older beta-blockers.
9. Neb. Nebzmart (Levosalbutamol + Ipratropium)
MOA:
- Levosalbutamol: Beta-2 adrenergic agonist → activates adenylyl cyclase → increases cAMP → relaxes bronchial smooth muscle → bronchodilation. R-enantiomer of salbutamol (fewer cardiac side effects than racemic mix).
- Ipratropium: Muscarinic (M3) antagonist → blocks ACh-mediated bronchoconstriction → bronchodilation, reduces secretions. Particularly useful in OAD/COPD.
10. Tab. Quinohike (Levofloxacin 500 mg)
MOA: Fluoroquinolone antibiotic. Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV → prevents DNA supercoil relaxation and chromosomal separation during replication → bactericidal effect. Broad spectrum coverage including atypical organisms (Mycoplasma, Legionella) - appropriate for LRTI.
SECTION 2: ADVERSE DRUG REACTIONS (ADRs) & SIDE EFFECTS
| Drug | Common Side Effects | Serious ADRs |
|---|---|---|
| Ambroxol/Guaifenesin | Nausea, diarrhea, gastric discomfort | Rare: allergic reactions, Stevens-Johnson syndrome |
| Acetylcysteine (Muconget) | Nausea, vomiting, stomatitis, unpleasant smell | Bronchospasm (inhaled form), rare anaphylaxis |
| Zincovit | GI upset if taken on empty stomach | Zinc toxicity with long-term overuse |
| Pantoprazole | Headache, diarrhea, flatulence, nausea | Hypomagnesemia (long-term), C. diff risk, osteoporosis (chronic use), vitamin B12 deficiency |
| Cinnarizine/Domperidone | Drowsiness (cin), dry mouth, headache | Domperidone: QT prolongation (cardiac risk!), tardive dyskinesia (long-term), elevated prolactin |
| Mirtazapine | Weight gain, sedation, increased appetite, dry mouth | QT prolongation (mild), serotonin syndrome (with other serotoninergic drugs), hyponatremia |
| Librax (Chlordiazepoxide + Clidinium) | Drowsiness, dry mouth, blurred vision, urinary retention | Dependence/withdrawal, paradoxical excitation; clidinium: urinary retention, constipation, glaucoma aggravation |
| Nebivolol | Fatigue, bradycardia, cold extremities, dizziness | Bronchospasm (in asthmatics/OAD!), hypoglycemia masking, rebound hypertension on abrupt withdrawal |
| Levosalbutamol + Ipratropium | Tremor, palpitations (levosalb), dry mouth (ipatropium), tachycardia | Hypokalemia (levosalbutamol), paradoxical bronchospasm, urinary retention (ipatropium in elderly) |
| Levofloxacin | GI upset, headache, insomnia, dizziness | QT prolongation, tendinopathy/tendon rupture, peripheral neuropathy, C. diff colitis, photo-sensitization |
SECTION 3: DRUG-DRUG INTERACTIONS (DDIs)
🔴 MAJOR / CLINICALLY SIGNIFICANT
| Interaction | Drugs Involved | Risk | Mechanism |
|---|---|---|---|
| QT Prolongation (Additive) | Levofloxacin + Domperidone + Mirtazapine | HIGH - risk of Torsades de Pointes, ventricular arrhythmia | All three independently prolong QT interval. Triple combination is dangerous, especially with tachycardia (PR 104) already present. |
| CNS Depression (Additive) | Mirtazapine + Chlordiazepoxide (Librax) | MODERATE-HIGH | Both cause CNS sedation - additive depression, excessive sedation, respiratory depression risk |
| Anticholinergic burden | Clidinium (Librax) + Ipratropium (Nebzmart) | MODERATE | Both are anticholinergics - additive effects: dry mouth, blurred vision, constipation, urinary retention, confusion |
| Bronchospasm risk | Nebivolol + OAD/Pulmonary fibrosis | MODERATE | Even selective beta-1 blockers can precipitate bronchospasm in patients with obstructive airway disease. Nebivolol is relatively safer but still a concern at 5 mg dose. |
🟡 MODERATE INTERACTIONS
| Interaction | Drugs Involved | Risk |
|---|---|---|
| Domperidone + Levofloxacin | CINOD + Quinohike | Domperidone is the primary QT concern when combined with fluoroquinolones |
| Mirtazapine + Levofloxacin | Mirago + Quinohike | Mild additive QT risk - monitor ECG |
| Levosalbutamol-induced hypokalemia + QT drugs | Nebzmart + Levofloxacin + Domperidone | Beta-2 agonist drives K+ into cells → hypokalemia → further QT prolongation risk |
| Pantoprazole + Mirtazapine | Pantop + Mirago | Pantoprazole noted in some studies to contribute to QTc prolongation in combination with psychiatric drugs (see QT literature) |
SECTION 4: PRESCRIPTION RECONCILIATION
✅ Appropriate Prescribing
| Drug | Justification |
|---|---|
| Levofloxacin OD x 10 days | Appropriate for LRTI/AFI - covers atypical organisms |
| Pantoprazole 40 mg OD | GI protection justified with multiple drugs (antibiotic, NSAIDs if any, steroids if any) |
| Nebzmart (Levosalb + Ipatropium) TID | First-line bronchodilator combination for OAD - appropriate |
| Nebivolol 5 mg OD | Appropriate for HTN; metabolically safer beta-blocker |
| Zincovit | Appropriate for anemia + general weakness; nutritional support |
| Ambroxol (Pulmoclear) | Appropriate mucokinetic for LRTI + OAD |
| Mirtazapine 25 mg | Possibly for anorexia, sleep disturbance, generalized weakness - mirtazapine at low doses (7.5-15 mg) stimulates appetite and aids sleep. 25 mg is unusual (standard tabs: 7.5/15/30/45 mg) - verify dose |
⚠️ CONCERNS & FLAGS
| Issue | Detail | Recommendation |
|---|---|---|
| Duplicate mucolytics | Pulmoclear (Ambroxol) + Muconget (Acetylcysteine) both prescribed - both are mucolytics | Review necessity - one is usually sufficient. Keep Acetylcysteine (also antioxidant - beneficial in pulmonary fibrosis) |
| Duplicate listing of Zincovit | Listed twice (#2 as "Syp Zincovit 5ml BD" and #6 as "Syp Zincovit 5ml once") | Clarify - if both are same drug, this is a duplication error. Likely once daily is correct |
| Mirtazapine dose | 25 mg not a standard tablet size - standard formulations: 7.5 mg, 15 mg, 30 mg, 45 mg | Clarify intended dose - likely 15 mg or 30 mg |
| QT risk triad | Domperidone (CINOD) + Levofloxacin + Mirtazapine | Get baseline ECG if not done; monitor QTc; consider stopping CINOD while levofloxacin is ongoing |
| Nebivolol in OAD | Beta-blocker use in obstructive airway disease requires caution | Monitor for wheeze/bronchospasm; ensure lowest effective dose; it is prescribed for renovascular HTN and benefit likely outweighs risk at 5 mg |
| Anticholinergic load | Clidinium (Librax) + Ipratropium (Nebzmart) | Combined anticholinergic burden - watch for urinary retention, constipation, confusion especially in this 50-year-old female |
| Librax in AFI + LRTI | Benzodiazepine (Chlordiazepoxide) can cause respiratory depression | Use with caution; may be needed for anxiety/GI spasm but limit duration |
| STOPPED drugs - Minipress XL (Prazosin) | Correctly stopped - alpha-1 blocker. May have been stopped due to hypotension risk when combined with nebivolol (both BP lowering) or reflex tachycardia concern | Appropriate to stop given PR already 104/min |
| STOPPED - CINOD & Muconget | Noted with "STOP" on original sheet | If stopped on review, good - reduces QT risk and mucolytic duplication |
SECTION 5: OVERALL CLINICAL SUMMARY
Key Safety Concern: The most pressing pharmacological concern in this prescription is the triple QT-prolonging combination of Levofloxacin + Domperidone (CINOD) + Mirtazapine. Given that the patient has a resting tachycardia (PR 104), active infection, and is on a nebulized beta-2 agonist (which causes hypokalemia), her risk of drug-induced Torsades de Pointes is elevated.
Recommended Actions:
- Obtain a 12-lead ECG - check baseline QTc before continuing combination
- Stop or hold Domperidone while levofloxacin course is ongoing (10 days)
- Monitor serum potassium - levosalbutamol can drop K+, worsening QT risk
- Clarify Mirtazapine dose - 25 mg is not a standard tablet size
- Remove duplicate Zincovit listing
- Review need for two mucolytics - acetylcysteine alone is likely sufficient and beneficial in pulmonary fibrosis
- Monitor BP and HR daily - renovascular HTN with tachycardia needs tracking during antibiotic course
- Anticholinergic load monitoring - with both Clidinium and Ipratropium, watch for urinary retention and confusion
Disclaimer: This is a pharmacological analysis for educational/review purposes. All clinical decisions should be made by the treating physician with full patient history and examination.
Update tab minipress xl not stoped
Got it. Tab. Minipress XL (Prazosin) is NOT stopped - it is an active part of the prescription.
Here is the updated section with this correction applied throughout:
UPDATED DRUG LIST (Correction Applied)
| # | Drug (Brand) | Generic | Dose | Route | Frequency |
|---|---|---|---|---|---|
| 1 | Syp. Pulmoclear | Ambroxol + Guaifenesin | 5 ml | PO | BD |
| 2 | Syp. Zincovit | Zinc + Multivitamins | 5 ml | PO | OD |
| 3 | Syp. Muconget | Acetylcysteine | 10 ml | PO | BD |
| 4 | Tab. Pantoprazole | Pantoprazole | 40 mg | PO | OD |
| 5 | Tab. CINOD | Cinnarizine + Domperidone | 10 mg | PO | BD |
| 6 | Tab. Mirago | Mirtazapine | 25 mg | PO | OD |
| 7 | Tab. Librax | Chlordiazepoxide + Clidinium | 1 tab | PO | OD |
| 8 | Tab. Nebistar | Nebivolol | 5 mg | PO | OD |
| 9 | Tab. Minipress XL | Prazosin (extended release) | 5 mg | PO | OD ✅ ACTIVE |
| 10 | Neb. Nebzmart | Levosalbutamol + Ipratropium | 1 amp | Nebulization | TID |
| 11 | Tab. Quinohike | Levofloxacin | 500 mg | PO | OD x 10 days |
MOA of Tab. Minipress XL (Prazosin Extended Release)
Class: Selective alpha-1 adrenergic receptor blocker
MOA: Competitively blocks postsynaptic alpha-1 adrenoceptors in vascular smooth muscle → prevents norepinephrine-mediated vasoconstriction → reduces peripheral vascular resistance → lowers both systolic and diastolic BP. The XL (extended release) formulation provides smoother 24-hour blood pressure control and reduces first-dose hypotension. Also relaxes smooth muscle in the bladder neck and prostate (relevant in females too for urinary symptoms).
Indication here: Renovascular hypertension with BP 140/100 - used as add-on to Nebivolol.
Side Effects / ADRs:
- First-dose phenomenon: Sudden severe hypotension, syncope (especially with first dose or after dose increase)
- Postural/orthostatic hypotension - dizziness on standing
- Palpitations, reflex tachycardia
- Fluid retention, edema
- Headache, drowsiness
- Nasal congestion
UPDATED DDI - Additional Interaction with Minipress XL
🔴 NEW MAJOR CONCERN Added
| Interaction | Drugs | Risk | Detail |
|---|---|---|---|
| Hypotension (additive) | Minipress XL (Prazosin) + Nebivolol | HIGH | Both are antihypertensives. Prazosin (alpha-1 blocker) + Nebivolol (beta-1 blocker) combination = significant additive BP lowering. Risk of severe orthostatic hypotension and syncope, especially in a febrile, possibly dehydrated patient (AFI). |
| Reflex tachycardia worsened | Minipress XL alone | MODERATE | Alpha-1 blockade → vasodilation → baroreceptor reflex → tachycardia. Patient already has PR 104/min. Prazosin may worsen tachycardia. Nebivolol partially counteracts this (beta-blocker blunts reflex) but monitor HR carefully. |
| Hypotension + beta-2 agonist | Minipress XL + Levosalbutamol (Nebzmart) | MODERATE | Levosalbutamol causes vasodilation (beta-2 on vessels) + mild BP drop, which adds to prazosin-mediated hypotension |
UPDATED PRESCRIPTION RECONCILIATION FLAG
| Issue | Detail | Recommendation |
|---|---|---|
| Prazosin (Minipress XL) ACTIVE | Patient already has BP 140/100 + PR 104/min (tachycardia) + is febrile | Monitor BP closely - combination with Nebivolol risks over-lowering. Ensure patient is well hydrated. Advise against sudden standing (orthostatic precaution). |
| Dual antihypertensive therapy | Prazosin + Nebivolol | Rational combination (alpha + beta blockade) but requires close BP monitoring in an acutely ill febrile patient. Target BP should be 130/80 mmHg or lower per renovascular HTN guidelines. |
| Tachycardia concern | PR 104 with Prazosin on board | Alpha-1 blockade can worsen tachycardia. Nebivolol (beta-1 blockade) is the correct counterbalance. Ensure Nebivolol dose is adequate. |
Bottom line: With Minipress XL active, the patient is on dual antihypertensive therapy (alpha-blocker + beta-blocker). This is a rational combination for renovascular HTN, but in the setting of acute febrile illness, dehydration risk, and existing tachycardia, orthostatic hypotension and syncope are real risks. The QT triad (Levofloxacin + Domperidone + Mirtazapine) remains the top safety concern and should still be addressed with an ECG and potassium check.
Once again generate in one in short
PRESCRIPTION REVIEW - B. Vijay Laxmi | F | 50 yrs
Dx: AFI, LRTI, OAD, B/L Pulmonary Fibrosis | K/C/O: Renovascular HTN, Anemia
Vitals: Temp 99.6°F | BP 140/100 | PR 104/min | SpO2 97%
DRUGS + MOA + ADRs
| # | Drug | MOA | Key Side Effects |
|---|---|---|---|
| 1 | Syp. Pulmoclear (Ambroxol + Guaifenesin) 5ml BD | Stimulates surfactant, breaks mucus bonds, increases ciliary clearance; Guaifenesin hydrates mucus | Nausea, GI upset, rare allergic reaction |
| 2 | Syp. Zincovit (Zinc + Vitamins) 5ml OD | Cofactor for immunity + erythropoiesis; B12/folate for RBC maturation | GI upset on empty stomach |
| 3 | Syp. Muconget (Acetylcysteine) 10ml BD | Breaks disulfide bonds in mucus glycoproteins; antioxidant (glutathione precursor) | Nausea, stomatitis, bad odor |
| 4 | Tab. Pantoprazole 40mg OD | Irreversible H+/K+-ATPase inhibitor - blocks gastric acid secretion | Headache, diarrhea; long-term: hypomagnesemia, B12 deficiency |
| 5 | Tab. CINOD (Cinnarizine + Domperidone) 10mg BD | Cinnarizine: Ca2+ blocker + H1 blocker (anti-vertigo); Domperidone: D2 antagonist at CTZ (antiemetic, prokinetic) | Drowsiness; Domperidone: QT prolongation, hyperprolactinemia |
| 6 | Tab. Mirago (Mirtazapine) 25mg OD | NaSSA: blocks alpha-2 receptors → ↑NE + 5-HT release; blocks 5-HT2/5-HT3 + H1 → sedation + appetite stimulation | Weight gain, sedation, dry mouth; mild QT prolongation |
| 7 | Tab. Librax (Chlordiazepoxide 5mg + Clidinium 2.5mg) OD | Chlordiazepoxide: GABA-A positive modulator → anxiolytic; Clidinium: muscarinic antagonist → reduces GI spasm | Drowsiness, dry mouth, constipation, dependence risk |
| 8 | Tab. Nebistar (Nebivolol) 5mg OD | Beta-1 selective blocker + beta-3 → ↑NO → vasodilation; reduces HR + cardiac output | Fatigue, bradycardia, cold extremities; bronchospasm in OAD |
| 9 | Tab. Minipress XL (Prazosin ER) 5mg OD | Selective alpha-1 adrenoceptor blocker → vasodilation → ↓peripheral resistance → ↓BP | First-dose hypotension, orthostatic hypotension, palpitations, reflex tachycardia, edema |
| 10 | Neb. Nebzmart (Levosalbutamol + Ipratropium) 1amp TID | Levosalb: beta-2 agonist → ↑cAMP → bronchodilation; Ipratropium: M3 antagonist → blocks ACh bronchoconstriction | Tremor, tachycardia, hypokalemia (levosalb); dry mouth, urinary retention (ipatropium) |
| 11 | Tab. Quinohike (Levofloxacin) 500mg OD x 10d | Inhibits DNA gyrase + topoisomerase IV → bactericidal; covers atypicals (Mycoplasma, Legionella) | GI upset, insomnia; QT prolongation, tendon rupture, peripheral neuropathy |
DRUG-DRUG INTERACTIONS
| Severity | Pair | Risk |
|---|---|---|
| 🔴 Major | Levofloxacin + Domperidone + Mirtazapine | Triple QT prolongation → Torsades de Pointes risk. Patient has PR 104 + hypokalemia risk from Levosalbutamol - very high concern |
| 🔴 Major | Prazosin + Nebivolol | Additive hypotension + syncope risk, especially in febrile/dehydrated state |
| 🟡 Moderate | Mirtazapine + Chlordiazepoxide | Additive CNS + respiratory depression |
| 🟡 Moderate | Clidinium + Ipratropium | Additive anticholinergic burden → dry mouth, constipation, urinary retention, confusion |
| 🟡 Moderate | Nebivolol + OAD | Beta-blocker can worsen bronchospasm even if beta-1 selective |
| 🟡 Moderate | Prazosin + Levosalbutamol | Both vasodilatory → additive hypotension |
PRESCRIPTION RECONCILIATION
| Flag | Issue | Action |
|---|---|---|
| ⚠️ Duplicate mucolytic | Pulmoclear (Ambroxol) + Muconget (NAC) - both mucolytics | Keep one - prefer NAC (also antioxidant, beneficial in pulmonary fibrosis) |
| ⚠️ Duplicate Zincovit | Listed twice (BD and OD) | Clarify - OD is correct |
| ⚠️ Mirtazapine dose | 25 mg is not a standard tablet size (standard: 7.5/15/30/45 mg) | Verify - likely 15 mg intended |
| 🔴 QT triad active | Levofloxacin + Domperidone + Mirtazapine all on together | Get ECG; check serum K+; consider stopping Domperidone for 10-day antibiotic course |
| ⚠️ Tachycardia + Prazosin | PR 104 - alpha-1 blockade causes reflex tachycardia | Nebivolol counterbalances; monitor HR daily |
| ⚠️ Hypotension risk | Febrile patient on Prazosin + Nebivolol + Levosalbutamol | Ensure adequate hydration; advise slow position changes; monitor BP BD |
| ✅ Rational | Prazosin + Nebivolol (alpha + beta blockade) | Good combination for renovascular HTN if BP/HR monitored |
| ✅ Rational | Levofloxacin OD x 10d for LRTI | Appropriate spectrum + duration |
| ✅ Rational | Nebzmart TID for OAD | First-line bronchodilator therapy |
TOP 3 IMMEDIATE ACTIONS
- ECG now - check QTc before continuing Levofloxacin + Domperidone + Mirtazapine together
- Serum K+ - Levosalbutamol causes hypokalemia which worsens QT risk
- BP + HR monitoring BD - dual antihypertensive (Prazosin + Nebivolol) in febrile patient with PR 104 is a syncope/hypotension risk
Recheck for syp pulmoclear compositions
Searching the Web
Syp Pulmoclear composition ingredients India
Correction confirmed. The previous composition was wrong. Here is the accurate information:
✅ CORRECTED - Syp. Pulmoclear (Fourrts India Laboratories)
Actual Composition per 5 ml:
| Ingredient | Dose | Class |
|---|---|---|
| Acebrophylline | 50 mg | Bronchodilator + Mucolytic |
| Terbutaline | 1.25 mg | Beta-2 agonist (Bronchodilator) |
| Guaifenesin | 50 mg | Expectorant |
(Some formulations also contain Menthol 2.5 mg as a soothing agent)
CORRECTED MOA
- Acebrophylline: Inhibits phosphodiesterase → ↑cAMP in airway smooth muscle → bronchodilation + mucolytic (thins mucus). Dual action drug.
- Terbutaline: Beta-2 adrenergic agonist → ↑cAMP → bronchial smooth muscle relaxation → bronchodilation. Also inhibits mast cell mediator release.
- Guaifenesin: Expectorant - increases respiratory fluid secretion, reduces mucus adhesiveness, facilitates expectoration.
UPDATED SIDE EFFECTS (Corrected)
| Side Effect | Drug Responsible |
|---|---|
| Tremor, palpitations, tachycardia | Terbutaline (beta-2 agonist) |
| Hypokalemia | Terbutaline (drives K+ intracellularly) |
| Nausea, GI upset | Guaifenesin |
| Headache, dizziness | Acebrophylline |
| Hyperglycemia | Terbutaline (caution in diabetics) |
⚠️ UPDATED DDI ALERT (Important Addition)
Since Pulmoclear contains Terbutaline (beta-2 agonist) AND the patient is also on Nebzmart (Levosalbutamol - another beta-2 agonist):
| 🔴 NEW Interaction | Pulmoclear (Terbutaline) + Nebzmart (Levosalbutamol) |
|---|---|
| Risk | Additive beta-2 stimulation → excessive tachycardia, tremor, severe hypokalemia, hyperglycemia |
| Concern | Patient already has PR 104/min. Two beta-2 agonists together (oral + nebulized) significantly worsen tachycardia and hypokalemia, which further worsens QT prolongation risk |
| Action | Review necessity of both - one beta-2 agonist route is usually sufficient. Prioritize nebulized route (Nebzmart) for OAD. Monitor K+ and cardiac rhythm. |
Previous error corrected: Pulmoclear is NOT Ambroxol - it is Acebrophylline + Terbutaline + Guaifenesin, manufactured by Fourrts India Laboratories.
Now do everything in one brand name ,generic name , compositions, moa , indications , ADRS, SIDE EFFECTS , IMMEDIATE ACTIONS
COMPLETE PRESCRIPTION DRUG PROFILE
Patient: B. Vijay Laxmi | F | 50 yrs | BP 140/100 | PR 104 | SpO2 97% | Temp 99.6°F
Dx: AFI, LRTI, OAD, B/L Pulmonary Fibrosis | K/C/O: Renovascular HTN, Anemia
1. SYP. PULMOCLEAR
| Field | Details |
|---|---|
| Brand Name | Pulmoclear Syrup |
| Generic Name | Acebrophylline + Terbutaline + Guaifenesin |
| Composition | Acebrophylline 50mg + Terbutaline 1.25mg + Guaifenesin 50mg per 5ml |
| Manufacturer | Fourrts India Laboratories Pvt Ltd |
| MOA | Acebrophylline: Inhibits phosphodiesterase → ↑cAMP → bronchodilation + mucolytic (thins mucus). Terbutaline: Beta-2 agonist → ↑cAMP → bronchial smooth muscle relaxation. Guaifenesin: Increases airway fluid secretion → reduces mucus viscosity → facilitates expectoration |
| Indications | Bronchial asthma, COPD, OAD, LRTI with productive cough, bronchitis, emphysema |
| ADRs | Hypokalemia (terbutaline), hyperglycemia, paradoxical bronchospasm, tachycardia, tremor |
| Side Effects | Tremor, palpitations, nausea, GI upset, headache, dizziness, dry mouth |
| Immediate Action | ⚠️ Patient also on Nebzmart (Levosalbutamol) - TWO beta-2 agonists simultaneously → monitor K+, HR, blood glucose. PR already 104 - watch for worsening tachycardia |
2. SYP. ZINCOVIT
| Field | Details |
|---|---|
| Brand Name | Zincovit Syrup |
| Generic Name | Zinc Sulphate + Vitamins (A, B1, B2, B3, B5, B6, B9, B12, C, D3, E) + Grape Seed Extract |
| Composition | Zinc 4mg + Multivitamin complex per 5ml |
| Manufacturer | Apex Laboratories Pvt Ltd |
| MOA | Zinc: Cofactor for 300+ enzymes, essential for immune function, wound healing, protein synthesis. B12 + Folic acid: Required for DNA synthesis and RBC maturation. Vitamin C: Antioxidant + enhances iron absorption. Vitamin D3: Calcium homeostasis, immune modulation |
| Indications | Nutritional deficiency, anemia (adjunct), general weakness, immunity support, convalescence |
| ADRs | Zinc toxicity with prolonged overuse (nausea, metallic taste, copper deficiency) |
| Side Effects | GI upset, nausea if taken on empty stomach, metallic taste |
| Immediate Action | ✅ Safe. Give after food. Confirm once daily dosing - listed twice in prescription (BD vs OD) - clarify duplication |
3. SYP. MUCONGET
| Field | Details |
|---|---|
| Brand Name | Muconget Syrup |
| Generic Name | Acetylcysteine (N-Acetylcysteine / NAC) |
| Composition | Acetylcysteine 100mg per 5ml (10ml = 200mg) |
| Manufacturer | Various (commonly Hetero/Sun Pharma generics) |
| MOA | Free sulfhydryl (-SH) group directly breaks disulfide (-S-S-) bonds in mucus glycoproteins → reduces mucus viscosity and elasticity. Also replenishes glutathione (antioxidant) → cytoprotective effect. In pulmonary fibrosis: reduces oxidative stress in lung parenchyma |
| Indications | Productive cough, LRTI, COPD, mucolytic in pulmonary fibrosis (antioxidant role), paracetamol overdose antidote |
| ADRs | Bronchospasm (rare, especially in asthma/OAD), anaphylactoid reaction |
| Side Effects | Nausea, vomiting, stomatitis, unpleasant sulfur odor, GI discomfort |
| Immediate Action | ⚠️ Duplicate mucolytic - Pulmoclear already contains mucolytic (Acebrophylline). NAC preferred here due to antioxidant benefit in pulmonary fibrosis. Consider stopping Pulmoclear's mucolytic overlap or rationalizing |
4. TAB. PANTOP (PANTOPRAZOLE)
| Field | Details |
|---|---|
| Brand Name | Pantop 40 |
| Generic Name | Pantoprazole Sodium |
| Composition | Pantoprazole 40mg per tablet |
| Manufacturer | Aristo Pharmaceuticals Pvt Ltd |
| MOA | Proton Pump Inhibitor (PPI). Irreversibly binds H+/K+-ATPase on gastric parietal cell luminal surface → blocks final step of gastric acid secretion → reduces acid output by ~98%. Requires acidic environment for activation (prodrug activated in parietal cell canaliculi) |
| Indications | GERD, peptic ulcer disease, GI protection during NSAID/antibiotic/steroid therapy, stress ulcer prophylaxis, Zollinger-Ellison syndrome |
| ADRs | Long-term: Hypomagnesemia, hyponatremia, Vitamin B12 deficiency, iron malabsorption, osteoporosis, increased C. difficile risk, community-acquired pneumonia risk |
| Side Effects | Headache, diarrhea, flatulence, nausea, abdominal pain |
| Immediate Action | ✅ Appropriate GI protection. Give 30 min before breakfast. Monitor Mg2+ if on long-term therapy |
5. TAB. CINOD (CINNARIZINE + DOMPERIDONE)
| Field | Details |
|---|---|
| Brand Name | CINOD / Vertin-D / Stugeron-D |
| Generic Name | Cinnarizine + Domperidone |
| Composition | Cinnarizine 20mg + Domperidone 10mg per tablet |
| Manufacturer | Various (Sun Pharma, Torrent) |
| MOA | Cinnarizine: Calcium channel blocker (vascular) + H1 antihistamine + anti-serotonin → reduces labyrinthine excitability, cerebral vasodilator → anti-vertigo. Domperidone: Peripheral D2 dopamine receptor antagonist at chemoreceptor trigger zone (CTZ) and gastric wall → antiemetic + prokinetic. Does NOT cross BBB significantly |
| Indications | Vertigo, nausea, vomiting, motion sickness, vestibular disorders, gastroparesis |
| ADRs | Domperidone: QT prolongation (MAJOR), Torsades de Pointes, hyperprolactinemia (galactorrhea, gynecomastia), tardive dyskinesia (long-term) |
| Side Effects | Drowsiness (cinnarizine), dry mouth, headache, extrapyramidal symptoms (rare), weight gain |
| Immediate Action | 🔴 HOLD Domperidone while Levofloxacin is ongoing - both prolong QT. Get ECG before restarting. Check indication for Cinnarizine in this patient (vertigo not listed in diagnosis) |
6. TAB. MIRAGO (MIRTAZAPINE)
| Field | Details |
|---|---|
| Brand Name | Mirago / Mirtaz / Mirtawin |
| Generic Name | Mirtazapine |
| Composition | Mirtazapine 7.5mg / 15mg / 30mg / 45mg tablets (25mg NOT a standard size - verify) |
| Manufacturer | Various (Sun Pharma, Torrent, Intas) |
| MOA | NaSSA (Noradrenergic & Specific Serotonergic Antidepressant). Blocks presynaptic alpha-2 autoreceptors and heteroreceptors → disinhibits NE and 5-HT release. Simultaneously blocks 5-HT2A, 5-HT2C, 5-HT3 receptors → channels serotonin via 5-HT1A only → avoids nausea + sexual SE. Strong H1 blockade → sedation + appetite stimulation (beneficial here for weakness/anorexia) |
| Indications | Depression, anxiety, insomnia, appetite stimulation (in debilitated/elderly patients), chemotherapy-induced nausea |
| ADRs | QT prolongation (mild but additive risk), serotonin syndrome (with MAOIs/serotinergic drugs), hyponatremia (SIADH), agranulocytosis (rare but serious), seizure lowering |
| Side Effects | Weight gain, excessive sedation, increased appetite, dry mouth, constipation, dizziness |
| Immediate Action | ⚠️ Verify dose - 25mg not standard. Check QT in combination with Levofloxacin + Domperidone. Use with caution with Librax (additive sedation + CNS depression). Monitor for excessive sedation |
7. TAB. LIBRAX
| Field | Details |
|---|---|
| Brand Name | Librax |
| Generic Name | Chlordiazepoxide + Clidinium Bromide |
| Composition | Chlordiazepoxide 5mg + Clidinium 2.5mg per tablet |
| Manufacturer | Viatris (Pfizer) |
| MOA | Chlordiazepoxide: Benzodiazepine - positive allosteric modulator at GABA-A receptors → increases Cl- channel opening frequency → neuronal hyperpolarization → anxiolytic, muscle relaxant, sedative. Clidinium: Quaternary anticholinergic (muscarinic M1/M3 antagonist) → reduces GI smooth muscle spasm + decreases gastric acid secretion |
| Indications | Anxiety with GI spasm, IBS (irritable bowel syndrome), peptic ulcer with anxiety, functional dyspepsia |
| ADRs | Dependence and withdrawal syndrome (chlordiazepoxide), respiratory depression, paradoxical excitation; Clidinium: urinary retention, acute angle-closure glaucoma, paralytic ileus |
| Side Effects | Drowsiness, dry mouth, blurred vision, constipation, urinary hesitancy, confusion (elderly) |
| Immediate Action | ⚠️ Additive CNS depression with Mirtazapine - monitor sedation level. Additive anticholinergic load with Ipratropium (Nebzmart) - watch urinary retention. Limit duration due to dependence risk. Not suitable long-term |
8. TAB. NEBISTAR (NEBIVOLOL)
| Field | Details |
|---|---|
| Brand Name | Nebistar / Nebilet / Nodon |
| Generic Name | Nebivolol Hydrochloride |
| Composition | Nebivolol 5mg per tablet |
| Manufacturer | Strides Pharma / Menarini |
| MOA | Third-generation beta-1 selective adrenoceptor blocker + stimulates beta-3 receptors on endothelium → activates eNOS → increases NO production → vasodilation. Reduces HR, reduces cardiac output, reduces renin secretion, lowers peripheral resistance. Metabolically neutral (no adverse lipid/glucose effects unlike older beta-blockers) |
| Indications | Hypertension, heart failure (stable chronic), angina, rate control in tachyarrhythmias |
| ADRs | Bronchospasm (even with beta-1 selectivity - caution in OAD!), masking hypoglycemia, rebound hypertension on abrupt withdrawal, bradycardia, AV block |
| Side Effects | Fatigue, dizziness, cold extremities, bradycardia, headache, GI upset |
| Immediate Action | ⚠️ Use cautiously in OAD/pulmonary fibrosis - beta-1 selectivity is relative, not absolute. Monitor PR (already 104 - nebivolol should bring this down). NEVER stop abruptly. Monitor for bronchospasm after each nebulization |
9. TAB. MINIPRESS XL (PRAZOSIN ER)
| Field | Details |
|---|---|
| Brand Name | Minipress XL |
| Generic Name | Prazosin Hydrochloride (Extended Release) |
| Composition | Prazosin 5mg (extended release OROS technology) per tablet |
| Manufacturer | Pfizer Ltd |
| MOA | Selective competitive alpha-1 adrenoceptor blocker → prevents NE-mediated vasoconstriction in arteriolar smooth muscle → reduces peripheral vascular resistance → lowers both systolic and diastolic BP. XL formulation provides gradual sustained release → avoids peak plasma spikes → reduces first-dose syncope risk. Also relaxes smooth muscle in bladder neck |
| Indications | Hypertension (especially renovascular), benign prostatic hyperplasia (BPH), Raynaud's phenomenon, PTSD (nightmares) |
| ADRs | First-dose phenomenon (severe hypotension + syncope), orthostatic hypotension, fluid retention, reflex tachycardia |
| Side Effects | Dizziness, palpitations, nasal congestion, headache, edema, fatigue, drowsiness |
| Immediate Action | 🔴 Combined with Nebivolol → additive hypotension. Patient is febrile + tachycardic (PR 104) → high syncope risk. Monitor BP lying + standing (postural BP). Ensure adequate hydration. Advise patient to rise slowly. Check if orthostatic hypotension present |
10. NEB. NEBZMART (LEVOSALBUTAMOL + IPRATROPIUM)
| Field | Details |
|---|---|
| Brand Name | Nebzmart / Duolin / Levolin-I |
| Generic Name | Levosalbutamol (Levalbuterol) + Ipratropium Bromide |
| Composition | Levosalbutamol 1.25mg + Ipratropium 0.5mg per nebulization unit dose |
| Manufacturer | Cipla Ltd / Sun Pharma |
| MOA | Levosalbutamol: R-enantiomer of salbutamol. Selective beta-2 agonist → activates adenylyl cyclase → ↑cAMP → phosphorylates myosin light chain kinase → bronchial smooth muscle relaxation → bronchodilation. Fewer cardiac side effects than racemic salbutamol. Ipratropium: Quaternary anticholinergic → blocks M3 muscarinic receptors in bronchial smooth muscle → prevents ACh-mediated bronchoconstriction → bronchodilation + reduces secretions. Acts on large airways (complementary to levosalbutamol which acts on small airways) |
| Indications | COPD, OAD, acute severe asthma, bronchospasm, emphysema - first-line combination bronchodilator |
| ADRs | Levosalbutamol: Hypokalemia (drives K+ intracellularly), hyperglycemia, tachycardia, paradoxical bronchospasm. Ipratropium: Urinary retention, acute angle-closure glaucoma (eye exposure), dry mouth |
| Side Effects | Tremor, palpitations, throat dryness, cough, headache, taste disturbance |
| Immediate Action | ⚠️ Combined with Pulmoclear (Terbutaline) = TWO beta-2 agonists → excessive tachycardia + severe hypokalemia. Monitor K+ urgently. Nebulize TID as prescribed but watch HR after each dose. Avoid eye exposure with nebulizer mask |
11. TAB. QUINOHIKE (LEVOFLOXACIN)
| Field | Details |
|---|---|
| Brand Name | Quinohike / Levoflox / Levaquin |
| Generic Name | Levofloxacin |
| Composition | Levofloxacin 500mg per tablet |
| Manufacturer | Various (Cipla, Dr Reddy's, Macleods) |
| MOA | Fluoroquinolone antibiotic. L-isomer of ofloxacin. Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV → prevents DNA supercoil relaxation and chromosomal segregation during replication → double-strand DNA breaks → bactericidal. Concentration-dependent killing. Covers Gram +ve, Gram -ve, and atypical organisms (Mycoplasma, Chlamydia, Legionella) |
| Indications | LRTI, community-acquired pneumonia, acute exacerbation of chronic bronchitis, UTI, sinusitis, skin infections, AFI with suspected bacterial source |
| ADRs | QT prolongation (MAJOR), tendinopathy/tendon rupture (esp. Achilles, with steroids/elderly), peripheral neuropathy, C. difficile colitis, phototoxicity, seizures (lowers seizure threshold), dysglycemia |
| Side Effects | Nausea, diarrhea, headache, insomnia, dizziness, abdominal discomfort |
| Immediate Action | 🔴 QT prolongation risk - DO NOT combine with Domperidone without ECG check. Monitor QTc. Counsel patient: avoid sunlight (photosensitivity), take plenty of water, stop immediately if tendon pain develops, avoid antacids/PPI within 2 hours (reduces absorption) |
MASTER SAFETY ALERT SUMMARY
🔴 CRITICAL - Act Now
| # | Alert | Drugs Involved | Action |
|---|---|---|---|
| 1 | Triple QT Prolongation | Levofloxacin + Domperidone + Mirtazapine | Get 12-lead ECG immediately. Hold Domperidone. Check serum K+ |
| 2 | Double Beta-2 Agonist | Pulmoclear (Terbutaline) + Nebzmart (Levosalbutamol) | Check serum K+ urgently. Monitor HR after each dose. Review need for both |
| 3 | Dual Antihypertensive in febrile tachycardic patient | Prazosin XL + Nebivolol | Monitor lying/standing BP. Ensure hydration. Watch for syncope |
⚠️ MODERATE - Monitor Closely
| # | Alert | Drugs Involved | Action |
|---|---|---|---|
| 4 | Additive CNS depression | Mirtazapine + Chlordiazepoxide | Monitor sedation, respiratory rate |
| 5 | Additive Anticholinergic load | Clidinium (Librax) + Ipratropium (Nebzmart) | Watch urinary retention, constipation, confusion |
| 6 | Beta-blocker in OAD | Nebivolol | Monitor for wheeze/bronchospasm |
| 7 | Dose error | Mirtazapine 25mg | Verify - not a standard tablet size. Likely 15mg intended |
| 8 | Duplicate mucolytic | Pulmoclear + Muconget | Rationalize - keep NAC (Muconget) for antioxidant benefit in pulmonary fibrosis |
| 9 | Duplicate Zincovit | Listed BD + OD | Confirm OD only |
Make it short
PRESCRIPTION DRUG PROFILES - SHORT
B. Vijay Laxmi | F | 50y | AFI, LRTI, OAD, Pulmonary Fibrosis, HTN, Anemia
1. SYP. PULMOCLEAR
- Generic: Acebrophylline + Terbutaline + Guaifenesin
- Composition: Acebrophylline 50mg + Terbutaline 1.25mg + Guaifenesin 50mg / 5ml
- MOA: Acebrophylline → PDE inhibitor → bronchodilation + mucolytic | Terbutaline → Beta-2 agonist → bronchodilation | Guaifenesin → expectorant
- Indication: OAD, LRTI, bronchitis, productive cough
- ADRs/SE: Tremor, tachycardia, hypokalemia, hyperglycemia, nausea
- ⚠️ Action: Two beta-2 agonists (Terbutaline + Levosalbutamol) - monitor K+ and HR
2. SYP. ZINCOVIT
- Generic: Zinc + Multivitamins (A, B-complex, C, D3, E)
- Composition: Zinc 4mg + vitamin complex / 5ml
- MOA: Zinc - immune cofactor, erythropoiesis | B12/Folate - RBC maturation | Vit C - antioxidant, iron absorption
- Indication: Anemia, general weakness, nutritional deficiency
- ADRs/SE: Nausea (empty stomach), metallic taste
- ✅ Action: Give after food. Clarify dose - listed twice (BD vs OD)
3. SYP. MUCONGET
- Generic: Acetylcysteine (NAC)
- Composition: Acetylcysteine 100mg / 5ml
- MOA: Breaks disulfide bonds in mucus → reduces viscosity | Antioxidant (glutathione precursor) → benefits pulmonary fibrosis
- Indication: Productive cough, LRTI, pulmonary fibrosis (antioxidant)
- ADRs/SE: Nausea, stomatitis, sulfur odor, rare bronchospasm
- ⚠️ Action: Duplicate mucolytic with Pulmoclear - NAC preferred here (antioxidant benefit)
4. TAB. PANTOP (PANTOPRAZOLE)
- Generic: Pantoprazole Sodium
- Composition: 40mg tablet
- MOA: Irreversible H+/K+-ATPase inhibitor → blocks gastric acid secretion
- Indication: GI protection during antibiotic + multi-drug therapy
- ADRs/SE: Headache, diarrhea | Long-term: hypomagnesemia, B12 deficiency, osteoporosis
- ✅ Action: Give 30 min before breakfast. Safe and appropriate here
5. TAB. CINOD (CINNARIZINE + DOMPERIDONE)
- Generic: Cinnarizine + Domperidone
- Composition: Cinnarizine 20mg + Domperidone 10mg
- MOA: Cinnarizine → Ca2+ blocker + H1 antagonist → anti-vertigo | Domperidone → D2 antagonist at CTZ → antiemetic + prokinetic
- Indication: Vertigo, nausea, vomiting
- ADRs/SE: Drowsiness, dry mouth | Domperidone: QT prolongation, hyperprolactinemia
- 🔴 Action: HOLD Domperidone - QT risk with Levofloxacin + Mirtazapine. Get ECG first
6. TAB. MIRAGO (MIRTAZAPINE)
- Generic: Mirtazapine
- Composition: 7.5/15/30/45mg (25mg NOT standard - verify dose)
- MOA: NaSSA - blocks alpha-2 receptors → ↑NE + 5-HT | blocks H1 → sedation + appetite stimulation | blocks 5-HT2/5-HT3 → fewer GI side effects
- Indication: Depression, anorexia, insomnia, appetite stimulation in weak/debilitated patients
- ADRs/SE: Weight gain, sedation, dry mouth | Mild QT prolongation, agranulocytosis (rare)
- ⚠️ Action: Confirm dose. Additive sedation with Librax. Part of QT triad - get ECG
7. TAB. LIBRAX
- Generic: Chlordiazepoxide + Clidinium Bromide
- Composition: Chlordiazepoxide 5mg + Clidinium 2.5mg
- MOA: Chlordiazepoxide → GABA-A modulator → anxiolytic | Clidinium → M1/M3 anticholinergic → reduces GI spasm
- Indication: Anxiety with GI spasm, IBS, functional dyspepsia
- ADRs/SE: Drowsiness, dry mouth, blurred vision, constipation, dependence
- ⚠️ Action: Additive sedation with Mirtazapine. Additive anticholinergic with Ipratropium (Nebzmart). Limit duration
8. TAB. NEBISTAR (NEBIVOLOL)
- Generic: Nebivolol HCl
- Composition: 5mg tablet
- MOA: Beta-1 selective blocker + beta-3 → ↑NO → vasodilation → lowers HR + BP. Metabolically neutral
- Indication: Renovascular HTN, heart failure
- ADRs/SE: Fatigue, bradycardia, cold extremities | Bronchospasm in OAD
- ⚠️ Action: Monitor for bronchospasm post-nebulization. NEVER stop abruptly. Monitor PR daily
9. TAB. MINIPRESS XL (PRAZOSIN ER)
- Generic: Prazosin HCl Extended Release
- Composition: 5mg (OROS extended release)
- MOA: Selective alpha-1 blocker → prevents NE vasoconstriction → ↓peripheral resistance → ↓BP. XL = sustained release, avoids peak hypotension
- Indication: Renovascular HTN
- ADRs/SE: First-dose hypotension, orthostatic hypotension, reflex tachycardia, edema, dizziness
- 🔴 Action: Prazosin + Nebivolol = dual antihypertensive in febrile patient (PR 104) → syncope risk. Monitor postural BP. Ensure hydration
10. NEB. NEBZMART (LEVOSALBUTAMOL + IPRATROPIUM)
- Generic: Levosalbutamol + Ipratropium Bromide
- Composition: Levosalbutamol 1.25mg + Ipratropium 0.5mg / unit dose
- MOA: Levosalbutamol → Beta-2 agonist → ↑cAMP → bronchodilation (small airways) | Ipratropium → M3 antagonist → blocks ACh bronchoconstriction (large airways). Complementary dual bronchodilation
- Indication: OAD, COPD, acute bronchospasm - first-line combination
- ADRs/SE: Tremor, tachycardia, hypokalemia (levosalb) | Dry mouth, urinary retention (ipratropium)
- ⚠️ Action: Combined with Pulmoclear (Terbutaline) = double beta-2 agonist. Check K+. Avoid mask-eye contact (glaucoma risk)
11. TAB. QUINOHIKE (LEVOFLOXACIN)
- Generic: Levofloxacin
- Composition: 500mg tablet
- MOA: Fluoroquinolone → inhibits DNA gyrase + topoisomerase IV → bactericidal. Covers Gram+/Gram- + atypicals (Mycoplasma, Legionella)
- Indication: LRTI, CAP, AFI with bacterial source
- ADRs/SE: QT prolongation, tendon rupture, peripheral neuropathy, C. diff colitis, phototoxicity
- 🔴 Action: Do NOT combine with Domperidone without ECG. Avoid antacids within 2 hrs. Sunscreen advised. Stop if tendon pain occurs
🔴 TOP SAFETY ALERTS
| Priority | Issue | Action |
|---|---|---|
| 🔴 1 | QT Triad: Levofloxacin + Domperidone + Mirtazapine | ECG now + serum K+ |
| 🔴 2 | Double Beta-2: Pulmoclear (Terbutaline) + Nebzmart (Levosalbutamol) | Check K+, monitor HR |
| 🔴 3 | Dual antihypertensive in febrile tachycardic patient | Postural BP monitoring, hydration |
| ⚠️ 4 | Anticholinergic load: Clidinium + Ipratropium | Watch urinary retention |
| ⚠️ 5 | Mirtazapine dose 25mg - not standard | Verify with prescriber |
| ⚠️ 6 | Zincovit duplicate listing | Confirm OD only |
Update patient with pulmonary kcohs
"Pulmonary Kcohs" — this is likely Pulmonary Koch's = Pulmonary Tuberculosis (PTB).
This is a significant update to the clinical picture. Here is what changes:
UPDATED DIAGNOSIS
B. Vijay Laxmi | F | 50y
Dx: AFI | LRTI | OAD | B/L Pulmonary Fibrosis | Pulmonary Tuberculosis (Koch's)
K/C/O: Renovascular HTN | Anemia
CLINICAL IMPACT OF PULMONARY TB DIAGNOSIS
Why This Changes Everything
Pulmonary TB (Koch's) with bilateral pulmonary fibrosis suggests post-TB sequelae or active/partially treated TB with fibrotic changes - a common pattern in India.
KEY DRUG INTERACTIONS & CONCERNS WITH TB
🔴 LEVOFLOXACIN (Quinohike) - TB RELEVANCE
| Point | Detail |
|---|---|
| Critical concern | Levofloxacin is a second-line anti-TB drug (Group A fluoroquinolone in MDR-TB regimen) |
| Risk | Using levofloxacin alone as a 10-day course for LRTI in a TB patient → MASKS TB symptoms, induces fluoroquinolone resistance, converts drug-sensitive TB to MDR-TB |
| Guidelines | WHO/RNTCP strictly advises - fluoroquinolones should NOT be used empirically in suspected TB without ruling out TB first |
| 🔴 Action | Confirm TB status (sputum AFB, CBNAAT/GeneXpert) BEFORE continuing levofloxacin. If TB active → levofloxacin must be part of a formal TB regimen, NOT a standalone 10-day course |
🔴 MIRTAZAPINE (Mirago) + ANTI-TB DRUGS
| Point | Detail |
|---|---|
| If ATT started | Rifampicin (first-line ATT) is a potent CYP3A4 inducer → dramatically reduces mirtazapine plasma levels → loss of antidepressant effect |
| Action | If ATT initiated, mirtazapine dose will need to be increased significantly or alternative antidepressant chosen |
🔴 NEBIVOLOL + RIFAMPICIN (if ATT started)
| Point | Detail |
|---|---|
| Interaction | Rifampicin induces CYP2D6 → reduces nebivolol levels → BP control may fail |
| Action | Monitor BP closely if ATT started. May need dose adjustment |
⚠️ PANTOPRAZOLE + RIFAMPICIN
| Point | Detail |
|---|---|
| Interaction | Rifampicin reduces pantoprazole efficacy (CYP2C19 induction) |
| Action | May need higher PPI dose or switch to Rabeprazole (less CYP-dependent) |
⚠️ PYRAZINAMIDE (ATT drug) + RENOVASCULAR HTN
| Point | Detail |
|---|---|
| Concern | Pyrazinamide causes hyperuricemia → can worsen renovascular disease and contribute to hypertension |
| Action | Monitor uric acid levels if ATT started |
⚠️ ISONIAZID (ATT) + ANEMIA
| Point | Detail |
|---|---|
| Concern | INH causes pyridoxine (B6) deficiency → peripheral neuropathy + sideroblastic anemia - worsens existing anemia |
| Action | Pyridoxine (Vit B6) 10-25mg/day MUST be co-prescribed with INH. Zincovit contains B6 but dose may be insufficient |
⚠️ BILATERAL FIBROSIS + TB
| Point | Detail |
|---|---|
| Clinical note | B/L fibrosis in a TB patient = likely post-primary TB fibrosis or ongoing active TB with cavitation and fibrotic healing |
| SpO2 97% | Currently compensated but ATT hepatotoxicity can further stress lungs |
| Action | Baseline LFT, RFT, CBC, sputum AFB/CBNAAT before starting/continuing treatment |
UPDATED IMMEDIATE ACTIONS (with TB Added)
| Priority | Action |
|---|---|
| 🔴 1 | Sputum AFB smear + CBNAAT (GeneXpert) - confirm/rule out active TB before continuing levofloxacin |
| 🔴 2 | Stop levofloxacin if TB not ruled out - fluoroquinolone monotherapy in TB = drug resistance risk |
| 🔴 3 | ECG + serum K+ - QT triad (Levofloxacin + Domperidone + Mirtazapine) still active |
| 🔴 4 | If TB confirmed → start formal DOTS/ATT regimen (HRZE) under RNTCP and review all current drugs for Rifampicin interactions |
| ⚠️ 5 | Add Pyridoxine (B6) if INH started - prevents neuropathy + worsening anemia |
| ⚠️ 6 | Baseline LFT, RFT, CBC, uric acid before ATT |
| ⚠️ 7 | All previous alerts (double beta-2, dual antihypertensive, anticholinergic load) remain active |
Bottom line: Pulmonary Koch's fundamentally changes the management. Levofloxacin monotherapy in a TB patient is the single most dangerous prescribing decision here - it risks creating fluoroquinolone-resistant TB. Confirm TB status immediately.
Do as above give details Now do everything in one brand name ,generic name , compositions, moa , indications , ADRS, SIDE EFFECTS , IMMEDIATE ACTIONS
COMPLETE PRESCRIPTION DRUG PROFILES
B. Vijay Laxmi | F | 50y | AFI, LRTI, OAD, B/L Pulmonary Fibrosis, Pulmonary TB (Koch's)
K/C/O: Renovascular HTN, Anemia | BP 140/100 | PR 104 | SpO2 97% | Temp 99.6°F
1. SYP. PULMOCLEAR
| Field | Details |
|---|---|
| Brand Name | Pulmoclear Syrup |
| Generic Name | Acebrophylline + Terbutaline + Guaifenesin |
| Composition | Acebrophylline 50mg + Terbutaline 1.25mg + Guaifenesin 50mg per 5ml |
| MOA | Acebrophylline: PDE inhibitor → ↑cAMP → bronchodilation + breaks mucus bonds (mucolytic). Terbutaline: Beta-2 agonist → ↑cAMP → bronchial smooth muscle relaxation. Guaifenesin: Increases airway fluid → reduces mucus stickiness → expectorant |
| Indications | OAD, COPD, LRTI, bronchitis, asthma, productive cough |
| ADRs | Hypokalemia (terbutaline), hyperglycemia, paradoxical bronchospasm, tachyarrhythmia |
| Side Effects | Tremor, palpitations, nausea, GI upset, headache, dizziness |
| Immediate Action | 🔴 Terbutaline (beta-2) + Levosalbutamol (Nebzmart, beta-2) = DOUBLE beta-2 agonist → severe hypokalemia + tachycardia. Check serum K+ urgently. Monitor HR after each dose. In TB patient - productive cough may worsen with bronchodilators if cavitation present |
2. SYP. ZINCOVIT
| Field | Details |
|---|---|
| Brand Name | Zincovit Syrup |
| Generic Name | Zinc Sulphate + Vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D3, E + Grape Seed Extract |
| Composition | Zinc 4mg + Multivitamin complex per 5ml |
| MOA | Zinc: Cofactor for 300+ enzymes, immune function, cell-mediated immunity (important in TB). B12 + Folate: RBC maturation, DNA synthesis. Vit C: Antioxidant, enhances iron absorption. B6 (Pyridoxine): Nerve function, partially helps offset INH neuropathy |
| Indications | Anemia, general weakness, nutritional deficiency, immune support in TB |
| ADRs | Zinc toxicity (long-term excess): nausea, copper deficiency, immune suppression |
| Side Effects | GI upset, metallic taste if taken on empty stomach |
| Immediate Action | ⚠️ B6 content in Zincovit is LOW (usually 1-3mg). If INH (anti-TB) is started, Pyridoxine 10-25mg/day separately is MANDATORY to prevent INH-induced neuropathy and sideroblastic anemia. Clarify duplicate listing (BD vs OD) - OD is correct |
3. SYP. MUCONGET
| Field | Details |
|---|---|
| Brand Name | Muconget Syrup |
| Generic Name | Acetylcysteine (N-Acetylcysteine / NAC) |
| Composition | Acetylcysteine 100mg per 5ml (10ml dose = 200mg) |
| MOA | Free -SH group breaks disulfide bonds in mucus glycoproteins → reduces viscosity. Glutathione precursor → antioxidant → reduces oxidative lung damage in pulmonary fibrosis and TB-related lung injury |
| Indications | Productive cough, LRTI, pulmonary fibrosis (antioxidant), COPD, TB-associated mucus hypersecretion |
| ADRs | Bronchospasm (in reactive airway disease), anaphylactoid reaction (rare) |
| Side Effects | Nausea, vomiting, stomatitis, unpleasant sulfur odor |
| Immediate Action | ⚠️ Duplicate mucolytic with Pulmoclear (Acebrophylline). Keep NAC - superior choice in pulmonary fibrosis + TB lung injury due to antioxidant benefit. Consider rationalizing Pulmoclear. In TB with cavitation, excessive mucolysis can mobilize large volumes of secretions - monitor respiratory tolerance |
4. TAB. PANTOP (PANTOPRAZOLE)
| Field | Details |
|---|---|
| Brand Name | Pantop 40 |
| Generic Name | Pantoprazole Sodium |
| Composition | Pantoprazole 40mg per tablet |
| MOA | Irreversible H+/K+-ATPase (proton pump) inhibitor on gastric parietal cell → blocks final step of acid secretion → reduces gastric acid by ~98% |
| Indications | GI protection during multi-drug therapy (antibiotics, ATT), GERD, peptic ulcer, stress ulcer prophylaxis |
| ADRs | Long-term: Hypomagnesemia, B12 deficiency, iron malabsorption, osteoporosis, C. difficile infection risk |
| Side Effects | Headache, diarrhea, flatulence, nausea, abdominal pain |
| Immediate Action | ⚠️ If Rifampicin (ATT) started: Rifampicin induces CYP2C19 → reduces pantoprazole efficacy significantly. Consider switching to Rabeprazole (least CYP-dependent PPI) when ATT begins. Give 30 min before breakfast |
5. TAB. CINOD (CINNARIZINE + DOMPERIDONE)
| Field | Details |
|---|---|
| Brand Name | CINOD |
| Generic Name | Cinnarizine + Domperidone |
| Composition | Cinnarizine 20mg + Domperidone 10mg per tablet |
| MOA | Cinnarizine: Ca2+ channel blocker + H1 antihistamine + anti-serotonin → reduces vestibular excitability → anti-vertigo, anti-nausea. Domperidone: Peripheral D2 antagonist at CTZ + gastric wall → antiemetic + prokinetic. Minimal BBB penetration |
| Indications | Vertigo, nausea, vomiting, gastroparesis, motion sickness |
| ADRs | Domperidone: QT prolongation, Torsades de Pointes, hyperprolactinemia (galactorrhea), tardive dyskinesia (long-term) |
| Side Effects | Drowsiness, dry mouth, headache, extrapyramidal effects (rare) |
| Immediate Action | 🔴 HOLD Domperidone immediately - QT triad with Levofloxacin + Mirtazapine. Get ECG before restarting. In TB: nausea is common with ATT (especially Pyrazinamide + Rifampicin) so antiemetic will be needed later - choose safer alternative (e.g., Ondansetron) instead of Domperidone |
6. TAB. MIRAGO (MIRTAZAPINE)
| Field | Details |
|---|---|
| Brand Name | Mirago |
| Generic Name | Mirtazapine |
| Composition | Standard sizes: 7.5mg / 15mg / 30mg / 45mg (25mg NOT standard - verify) |
| MOA | NaSSA: Blocks alpha-2 presynaptic receptors → ↑NE + 5-HT release. Blocks 5-HT2A/2C/3 → fewer GI/sexual SE. Strong H1 blockade → sedation + appetite stimulation (beneficial for TB-related anorexia and weight loss) |
| Indications | Depression, anxiety, anorexia, insomnia, appetite stimulation in TB/debilitated patients, weight restoration |
| ADRs | Mild QT prolongation, agranulocytosis (rare - important as TB also causes bone marrow suppression), serotonin syndrome, hyponatremia |
| Side Effects | Weight gain, sedation, dry mouth, constipation, dizziness |
| Immediate Action | 🔴 Part of QT triad - get ECG. If Rifampicin started for TB: Rifampicin (CYP3A4 inducer) dramatically lowers mirtazapine levels → loss of effect → may need dose increase or drug change. Verify 25mg dose with prescriber. Monitor for agranulocytosis (CBC monthly) |
7. TAB. LIBRAX
| Field | Details |
|---|---|
| Brand Name | Librax |
| Generic Name | Chlordiazepoxide + Clidinium Bromide |
| Composition | Chlordiazepoxide 5mg + Clidinium 2.5mg per tablet |
| MOA | Chlordiazepoxide: Benzodiazepine → GABA-A positive modulator → ↑Cl- influx → neuronal hyperpolarization → anxiolytic + muscle relaxant. Clidinium: Quaternary anticholinergic (M1/M3 antagonist) → reduces GI smooth muscle spasm + gastric acid |
| Indications | Anxiety with GI spasm, IBS, functional dyspepsia |
| ADRs | Dependence and withdrawal (chlordiazepoxide), respiratory depression, paradoxical agitation. Clidinium: urinary retention, acute glaucoma, paralytic ileus |
| Side Effects | Drowsiness, dry mouth, blurred vision, constipation, confusion |
| Immediate Action | ⚠️ Additive CNS depression with Mirtazapine → monitor respiratory rate and sedation. Additive anticholinergic with Ipratropium (Nebzmart) → watch urinary retention. In TB: Hepatotoxicity of ATT + benzodiazepine metabolism via liver → monitor LFTs. Limit duration strictly |
8. TAB. NEBISTAR (NEBIVOLOL)
| Field | Details |
|---|---|
| Brand Name | Nebistar |
| Generic Name | Nebivolol Hydrochloride |
| Composition | Nebivolol 5mg per tablet |
| MOA | Beta-1 selective blocker + Beta-3 agonism → stimulates eNOS → ↑NO → vasodilation. Reduces HR, cardiac output, renin secretion. Metabolically neutral (no adverse glucose/lipid effects) |
| Indications | Hypertension (renovascular), stable heart failure, tachycardia control |
| ADRs | Bronchospasm (even beta-1 selective - caution in OAD/TB fibrosis), bradycardia, masking of hypoglycemia, rebound hypertension on abrupt withdrawal |
| Side Effects | Fatigue, dizziness, cold extremities, headache, bradycardia |
| Immediate Action | ⚠️ If Rifampicin started: Rifampicin induces CYP2D6 → reduces nebivolol plasma levels → BP control may fail. Monitor BP closely and adjust dose. Monitor post-nebulization for bronchospasm. NEVER stop abruptly. PR 104 - nebivolol should help bring HR down |
9. TAB. MINIPRESS XL (PRAZOSIN ER)
| Field | Details |
|---|---|
| Brand Name | Minipress XL |
| Generic Name | Prazosin Hydrochloride Extended Release |
| Composition | Prazosin 5mg (OROS extended release) per tablet |
| MOA | Selective alpha-1 adrenoceptor blocker → prevents NE-mediated vasoconstriction in arteriolar smooth muscle → ↓peripheral vascular resistance → ↓systolic + diastolic BP. XL formulation = gradual release → avoids first-dose peak hypotension |
| Indications | Renovascular hypertension, BPH, Raynaud's phenomenon |
| ADRs | First-dose phenomenon (severe hypotension + syncope), orthostatic hypotension, fluid retention, reflex tachycardia |
| Side Effects | Dizziness, palpitations, nasal congestion, headache, pedal edema, fatigue |
| Immediate Action | 🔴 Prazosin + Nebivolol = dual antihypertensive in febrile + tachycardic (PR 104) patient → high syncope risk. Check postural BP (lying vs standing). Ensure adequate hydration (fever → dehydration → worsens hypotension). In TB: if TB pericarditis or adrenal TB (rare) → BP can be labile |
10. NEB. NEBZMART (LEVOSALBUTAMOL + IPRATROPIUM)
| Field | Details |
|---|---|
| Brand Name | Nebzmart |
| Generic Name | Levosalbutamol + Ipratropium Bromide |
| Composition | Levosalbutamol 1.25mg + Ipratropium 0.5mg per unit dose vial |
| MOA | Levosalbutamol (R-enantiomer of salbutamol): Selective Beta-2 agonist → ↑cAMP → phosphorylates MLCK → bronchial smooth muscle relaxation → bronchodilation (small airways). Fewer cardiac SE than racemic salbutamol. Ipratropium: Quaternary M3 muscarinic antagonist → blocks ACh-mediated bronchoconstriction → bronchodilation (large airways). Complementary dual-pathway bronchodilation |
| Indications | OAD, COPD, acute bronchospasm, TB with obstructive component, pulmonary fibrosis with airflow limitation |
| ADRs | Levosalbutamol: Hypokalemia, hyperglycemia, tachycardia, paradoxical bronchospasm. Ipratropium: Urinary retention, acute angle-closure glaucoma (if aerosol contacts eye) |
| Side Effects | Tremor, palpitations, dry mouth, throat irritation, cough, taste disturbance |
| Immediate Action | 🔴 Combined with Pulmoclear (Terbutaline) = double beta-2 agonist → additive hypokalemia (worsens QT risk) + tachycardia. Serum K+ URGENT. Use tight-fitting mask to prevent eye exposure. In TB with cavitation: vigorous bronchodilation may mobilize secretions → ensure patient can expectorate safely |
11. TAB. QUINOHIKE (LEVOFLOXACIN)
| Field | Details |
|---|---|
| Brand Name | Quinohike |
| Generic Name | Levofloxacin |
| Composition | Levofloxacin 500mg per tablet |
| MOA | Fluoroquinolone antibiotic (L-isomer of ofloxacin). Inhibits bacterial DNA gyrase (Topoisomerase II) + Topoisomerase IV → prevents DNA supercoiling relaxation + chromosomal segregation → double-strand DNA breaks → bactericidal. Concentration-dependent killing. Spectrum: Gram+, Gram-, atypicals (Mycoplasma, Chlamydia, Legionella) |
| Indications | LRTI, CAP, AFI. Also: Second-line anti-TB drug (Group A fluoroquinolone in MDR-TB regimen) |
| ADRs | QT prolongation, tendinopathy/tendon rupture (esp. Achilles), peripheral neuropathy, C. difficile colitis, phototoxicity, seizures (lowers threshold), dysglycemia |
| Side Effects | Nausea, diarrhea, headache, insomnia, dizziness, abdominal discomfort |
| Immediate Action | 🔴🔴 CRITICAL IN TB PATIENT: Levofloxacin as standalone 10-day course in unconfirmed/active TB = MASKS TB + induces fluoroquinolone resistance = risk of MDR-TB. WHO/RNTCP guidelines prohibit empirical fluoroquinolone monotherapy without ruling out TB. Perform sputum AFB + CBNAAT (GeneXpert) IMMEDIATELY. Hold or integrate levofloxacin into formal ATT regimen only. Also: DO NOT combine with Domperidone without ECG. Avoid antacids/PPI within 2 hours. Use sunscreen |
MASTER SAFETY ALERTS
🔴 CRITICAL
| # | Alert | Drugs | Action |
|---|---|---|---|
| 1 | Fluoroquinolone in TB | Levofloxacin | Sputum AFB + CBNAAT NOW. Stop standalone use if TB confirmed |
| 2 | Triple QT prolongation | Levofloxacin + Domperidone + Mirtazapine | ECG + serum K+ immediately. Hold Domperidone |
| 3 | Double beta-2 agonist | Terbutaline (Pulmoclear) + Levosalbutamol (Nebzmart) | Serum K+ urgent. Monitor HR after each nebulization |
| 4 | Dual antihypertensive in febrile patient | Prazosin + Nebivolol | Postural BP monitoring. IV/oral hydration |
⚠️ MODERATE
| # | Alert | Drugs | Action |
|---|---|---|---|
| 5 | Rifampicin (ATT) interactions | Rifampicin vs Mirtazapine + Nebivolol + Pantoprazole | Monitor drug levels/effects when ATT starts. Adjust doses |
| 6 | Pyridoxine deficiency | INH (ATT) + existing anemia | Add Pyridoxine 25mg OD when INH started. Zincovit B6 insufficient |
| 7 | Additive CNS depression | Mirtazapine + Chlordiazepoxide | Monitor sedation + respiratory rate |
| 8 | Anticholinergic overload | Clidinium (Librax) + Ipratropium (Nebzmart) | Watch urinary retention, constipation, confusion |
| 9 | Beta-blocker in OAD + TB fibrosis | Nebivolol | Monitor for bronchospasm. Never stop abruptly |
| 10 | Mirtazapine 25mg dose error | Mirago | Verify with prescriber - not a standard size |
| 11 | Duplicate mucolytic | Pulmoclear + Muconget | Keep NAC. Review Pulmoclear |
| 12 | Duplicate Zincovit | Listed BD + OD | Confirm OD only |
BASELINE INVESTIGATIONS NEEDED NOW
Sputum AFB + CBNAAT | 12-lead ECG | Serum K+ | LFT | RFT | CBC | Uric acid | Postural BP
Recked quniohike
Searching the Web
Quinohike tablet composition generic name manufacturer India
Major correction confirmed. Quinohike is NOT Levofloxacin. Here is the accurate profile:
✅ CORRECTED - TAB. QUINOHIKE
| Field | Details |
|---|---|
| Brand Name | Quinohike Capsule |
| Generic Name | Ubidecarenone (Coenzyme Q10 / CoQ10) |
| Composition | CoQ10 200mg per capsule (HPMC capsule) |
| Manufacturer | La Renon Healthcare Private Limited, Ahmedabad |
| MOA | CoQ10 is a fat-soluble antioxidant naturally synthesized in the body from tyrosine. Acts as an electron carrier in the mitochondrial electron transport chain (Complex I-III) → essential for ATP production. Also stabilizes cell membranes, reduces oxidative stress, and has anti-inflammatory properties. In cardiovascular disease: improves myocardial energy metabolism |
| Indications | CoQ10 deficiency, mitochondrial disorders, statin-induced myopathy (muscle symptoms), cardiovascular support, hypertension adjunct, pulmonary hypertension, fatigue, fibromyalgia, general debility |
| ADRs | Generally very safe. Rare: mild GI upset, decreased anticoagulant effect (warfarin interaction) |
| Side Effects | Nausea, upset stomach, vomiting, diarrhea (mild, rare) |
| Immediate Action | ✅ Safe and appropriate in this patient - supports mitochondrial function in pulmonary fibrosis + TB lung disease (both cause oxidative stress). OD dosing x 10 days as prescribed is fine. No QT risk. No TB-masking concern |
⚠️ CRITICAL CORRECTION TO PREVIOUS ANALYSIS
| Previous (Wrong) | Corrected |
|---|---|
| Quinohike = Levofloxacin 500mg | Quinohike = CoQ10 200mg capsule |
| Listed as QT prolongation risk | NO QT risk - actually cardioprotective |
| Listed as TB fluoroquinolone resistance risk | NOT applicable - CoQ10 has no antibiotic activity |
| Prescribed as antibiotic for LRTI/AFI | Prescribed as mitochondrial/antioxidant support |
WHAT THIS MEANS FOR THE PRESCRIPTION
- No standalone fluoroquinolone is prescribed - the TB masking concern from previous analysis is withdrawn
- LRTI/AFI antibiotic cover needs to be reassessed - is there a separate antibiotic prescribed that was missed, or is the patient being managed conservatively?
- QT triad now reduces to: only Domperidone (CINOD) + Mirtazapine remain as QT concerns (still monitor but lower risk without levofloxacin)
- CoQ10 + Nebivolol - actually a beneficial combination: CoQ10 supports cardiac energy while Nebivolol controls BP
- CoQ10 in pulmonary fibrosis + TB - appropriate antioxidant support, may reduce oxidative lung damage
UPDATED TOP SAFETY ALERTS (Post-Correction)
| Priority | Alert | Status |
|---|---|---|
| 🔴 1 | Double beta-2 agonist (Terbutaline + Levosalbutamol) | Still active - check K+ |
| 🔴 2 | QT risk Domperidone + Mirtazapine | Reduced (no fluoroquinolone) but still monitor ECG |
| 🔴 3 | Dual antihypertensive Prazosin + Nebivolol in febrile patient | Still active |
| ✅ | TB masking by fluoroquinolone - WITHDRAWN | Not applicable |
| ✅ | Levofloxacin QT concern - WITHDRAWN | Not applicable |
| ⚠️ | No antibiotic identified for LRTI/AFI | Clarify with prescriber - is antibiotic therapy planned? |
ReCheck mirago
Searching the Web
Mirago tablet composition generic name manufacturer India
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
This is a shared conversation. Sign in to Orris to start your own chat.